



US009993555B2

(12) **United States Patent**
Akers et al.(10) **Patent No.:** **US 9,993,555 B2**
(45) **Date of Patent:** **Jun. 12, 2018**(54) **RAPID-ACTING INSULIN COMPOSITIONS**(71) Applicant: **ELI LILLY AND COMPANY**,
Indianapolis, IN (US)(72) Inventors: **Michael Patrick Akers**, Indianapolis,
IN (US); **Chi A. Nguyen**, Fishers, IN
(US); **Chad D. Paavola**, Carmel, IN
(US); **Virender Kumar Sarin**, Carmel,
IN (US); **Nanette Elizabeth Schulte**,
Indianapolis, IN (US); **Ranajoy Majumdar**, Indianapolis, IN (US)(73) Assignee: **Eli Lilly and Company**, Indianapolis,
IN (US)(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days. days.(21) Appl. No.: **14/963,279**(22) Filed: **Dec. 9, 2015**(65) **Prior Publication Data**

US 2016/0166695 A1 Jun. 16, 2016

Related U.S. Application Data(60) Provisional application No. 62/092,407, filed on Dec.
16, 2014.(51) **Int. Cl.****A61K 38/28** (2006.01)
A61K 47/12 (2006.01)
A61K 9/00 (2006.01)(52) **U.S. Cl.**CPC **A61K 47/12** (2013.01); **A61K 9/0019**
(2013.01); **A61K 38/28** (2013.01)(58) **Field of Classification Search**CPC A61K 38/28
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**

4,476,118 A	10/1984	Brange et al.
4,885,164 A	12/1989	Thurow
5,164,366 A	11/1992	Balschmidt et al.
5,474,978 A	12/1995	Bakaysa et al.
5,716,927 A	2/1998	Balschmidt et al.
5,866,538 A	2/1999	Norup et al.
7,279,457 B2	10/2007	Pohl et al.
7,696,162 B2	4/2010	Boderke
7,713,929 B2 *	5/2010	Steiner A61K 31/185
		514/5.9
7,713,930 B2	5/2010	Brunner-Schwarz et al.
8,084,420 B2	12/2011	Steiner et al.
8,318,154 B2	11/2012	Frost et al.
2007/0086952 A1	4/2007	Steiner et al.
2007/0235365 A1	10/2007	Pohl et al.
2008/0090753 A1	4/2008	Pohl et al.
2010/0167990 A1	7/2010	Poulsen et al.
2010/0227795 A1	9/2010	Steiner et al.
2010/0249020 A1	9/2010	Soula et al.
2012/0094902 A1	4/2012	Soula et al.
2012/0178675 A1	7/2012	Pohl et al.

2013/0011378 A1	1/2013	Yang et al.
2013/0022592 A1	1/2013	Vaughn et al.
2013/0231281 A1	9/2013	Soula et al.
2013/0302275 A1	11/2013	Nei et al.
2014/0113856 A1	4/2014	Pohl et al.
2014/0135682 A1	5/2014	Frost et al.
2014/0357554 A1	12/2014	Pohl et al.
2015/0065423 A1	3/2015	Laulicht et al.
2015/0273022 A1	10/2015	Wilson et al.

FOREIGN PATENT DOCUMENTS

EP	214826	3/1987
EP	280534	2/1988
WO	9733531	9/1997
WO	9749386	12/1997
WO	9934821	7/1999
WO	0043034	7/2000
WO	0135943	5/2001
WO	03000202	1/2003
WO	12006283	1/2012
WO	13158618	10/2013
WO	13177565	11/2013
WO	15106269	7/2015
WO	15120457	8/2015

OTHER PUBLICATIONS

Pohl, Roderike, et al., Ultra-Rapid Absorption of Recombinant Human Insulin Induced by Zinc Chelation and Surface Charge Masking, *J. Diabetes Sci Technol* 2012; 6(4), pp. 755-563.

Pohl, et al., "Development of Ultra-Rapid-Acting Prandial Insulin analogs Requires Chelation of Zinc Ions and Charge Masking to Increase the Rate of Subcutaneous Absorption," available at http://files.shareholder.com/downloads/BIOD/0x0x60291213C955886-6AA4-4D66-BD33-3FFB4C906B25/EASD_Poster_September_2012_FINAL.pdf.

Krasner, et al., "Lispro Formulations BIOD-238 and BIOD-250 Associated With Faster Absorption and Declines From Peak Concentrations Compared to Humalog®" available at http://files.shareholder.com/downloads/BIOD/2632769718x0x672700/BF867032-C746-4DB1-A80B-FFA9DE1E565B/Lispro_Formulations_BIOD-238_and_BIOD-250_Associated_With_Faster_Absorption__ADA_June_2013.PDF.

Capelle, M.A.H., et al., "High Throughput Screening of Protein Formulation Stability: Practical Considerations," *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 65, No. 2, Jan. 5, 2007, pp. 131-148.

Patent Cooperation Treaty International Search Report and Written Opinion of the International Searching Authority pertaining to International Application No. PCT/US2015/064744; International Filing Date: Dec. 9, 2015; dated Mar. 23, 2016.

Prabhu, S., Jacknowitz, A. I., & Stout, P. J. (2001). A study of factors controlling dissolution kinetics of zinc complexed protein suspensions in various ionic species. *International journal of pharmaceutics*, 217(1), 71-78.

* cited by examiner

Primary Examiner — Gyan Chandra

(74) *Attorney, Agent, or Firm* — Matthew T Lord

(57) **ABSTRACT**

The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.

12 Claims, No Drawings